Phase III study to clarify the efficacy and safety of aprepitant or palonosetron on chemotherapy with paclitaxel and carboplatin for gynecologic cancer
Phase 3
- Conditions
- Cervical cancer, Corpus cancer, Ovarian cancer, Tubal cancer, Peritoneal cancer
- Registration Number
- JPRN-UMIN000009585
- Lead Sponsor
- Obstetrics and Gynecology, Tokushima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Past history of previous chemotherapy 2. Hypersensitivity for Aprepitant or Palonosetron
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method